386 related articles for article (PubMed ID: 14617781)
21. Hepatocyte growth factor exerts multiple biological functions on bovine mammary epithelial cells.
Accornero P; Martignani E; Macchi E; Baratta M
J Dairy Sci; 2007 Sep; 90(9):4289-96. PubMed ID: 17699048
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins.
Weimar IS; de Jong D; Muller EJ; Nakamura T; van Gorp JM; de Gast GC; Gerritsen WR
Blood; 1997 Feb; 89(3):990-1000. PubMed ID: 9028331
[TBL] [Abstract][Full Text] [Related]
23. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
24. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant.
Parr C; Davies G; Nakamura T; Matsumoto K; Mason MD; Jiang WG
Biochem Biophys Res Commun; 2001 Aug; 285(5):1330-7. PubMed ID: 11478803
[TBL] [Abstract][Full Text] [Related]
25. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
Parr C; Ali AY
J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
[TBL] [Abstract][Full Text] [Related]
26. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
27. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
28. C-Met signalling in an HGF/SF-insensitive variant MDCK cell line with constitutive motile/invasive behaviour.
Webb CP; Lane K; Dawson AP; Vande Woude GF; Warn RM
J Cell Sci; 1996 Sep; 109 ( Pt 9)():2371-81. PubMed ID: 8886986
[TBL] [Abstract][Full Text] [Related]
29. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
30. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.
Fan S; Ma YX; Gao M; Yuan RQ; Meng Q; Goldberg ID; Rosen EM
Mol Cell Biol; 2001 Aug; 21(15):4968-84. PubMed ID: 11438654
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
32. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
33. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
34. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
35. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
[TBL] [Abstract][Full Text] [Related]
36. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells.
Accornero P; Miretti S; Starvaggi Cucuzza L; Martignani E; Baratta M
J Mol Endocrinol; 2010 Feb; 44(2):115-25. PubMed ID: 19850646
[TBL] [Abstract][Full Text] [Related]
38. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo.
Davies G; Mason MD; Martin TA; Parr C; Watkins G; Lane J; Matsumoto K; Nakamura T; Jiang WG
Int J Cancer; 2003 Sep; 106(3):348-54. PubMed ID: 12845672
[TBL] [Abstract][Full Text] [Related]
39. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.
Cassinelli G; Lanzi C; Petrangolini G; Tortoreto M; Pratesi G; Cuccuru G; Laccabue D; Supino R; Belluco S; Favini E; Poletti A; Zunino F
Mol Cancer Ther; 2006 Sep; 5(9):2388-97. PubMed ID: 16985073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
